Discontinuation rate due to TRAEs very low - 2 out of 41 treated patients even though only 38 used for efficacy - even lower than nivolumab alone in the background, how could dealing with AEs differently really affect response rate? Maybe academic centers enrolled patients with different baseline characteristics from other sites? This is generally true in all clinical trials, once you expand to larger number of sites, patients enrolled become much more diverse.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.